IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: No difference in the high-and low-risk groups
Mo, Xiao-Dong1,2; Xu, Lan-Ping1,2; Zhang, Xiao-Hui1,2; Liu, Dai-Hong1,2; Wang, Yu1,2; Chen, Huan1,2; Yan, Chen-Hua1,2; Chen, Yu-Hong1,2; Han, Wei1,2; Wang, Feng-Rong1,2; Wang, Jing-Zhi1,2; Liu, Kai-Yan1,2; Huang, Xiao-Jun1,2,3
关键词Philadelphia-negative acute lymphoblastic leukemia adult hematopoietic stem cell transplantation haploidentical
刊名INTERNATIONAL JOURNAL OF CANCER
2015-04-01
DOI10.1002/ijc.29146
136期:7页:1697-1707
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]BONE-MARROW-TRANSPLANTATION ; ACUTE MYELOID-LEUKEMIA ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; 1ST COMPLETE REMISSION ; MATCHED RELATED DONOR ; ABO INCOMPATIBILITY ; HEMATOLOGIC MALIGNANCIES ; POSTREMISSION THERAPY ; COMORBIDITY INDEX ; UNRELATED DONOR
英文摘要

Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective post-consolidation therapy and curative option for adult patients with Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL) in first complete remission (CR1). A human leukocyte antigen (HLA)-haploidentical related donor (haplo-RD) is one of the most important alternative sources for those without HLA-identical sibling donor (ISD). The present study aimed to evaluate the outcomes of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in adult Ph-negative ALL CR1 patients (n=183). We produced an unmanipulated haplo-HSCT protocol including granulocyte colony stimulating factor (G-CSF) for all donors, intensive immune suppression, anti-thymocyte globulin, and combination of G-CSF-primed bone marrow harvest and G-CSF-mobilized peripheral blood stem cells harvest as the source of stem cell grafts. The median age for high-risk versus low-risk groups were 29 versus 23 years. Three-year incidences of relapse mortality and nonrelapse mortality for high-risk versus low-risk groups were 7.1% versus 11.1% (p=0.498) and 18.0% versus 16.2% (p=0.717), respectively. Three-year probabilities of disease-free survival and overall survival for high-risk versus low-risk groups were 67.6% versus 68.2% (p=0.896) and 74.9% versus 72.7% (p=0.981), respectively. Multivariate analysis showed that limited cGVHD and a lower pre-HSCT comorbidity burden were associated with better outcomes. In summary, comparable outcomes were observed among high- and low-risk Ph-negative ALL CR1 patients after haplo-HSCT. Haplo-RD could be considered for adults with Ph-negative ALL in CR1 as an important alternative source of donors in cases when no ISD is available.

What′s new? Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective post-consolidation therapy for adult patients with Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL) in first complete remission (CR1). A human leukocyte antigen (HLA)-haploidentical related donor (haplo-RD) is an important alternative source for those without HLA-identical sibling donor (ISD). Here, comparable outcomes were observed among high- and low-risk Ph-negative ALL CR1 patients after haplo-HSCT, and haplo-HSCT might overcome the poor prognostic significance of a high-risk status of Ph-negative ALL CR1 at diagnosis. Haplo-RDs may thus be considered for Ph-negative ALL adult patients in CR1 as an important alternative source of donors.

语种英语
WOS记录号WOS:000348443400024
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63210
专题北京大学第二临床医学院
医学人文研究院/公共教学部_哲学与社会科学系
北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Peking Univ, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
3.Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Mo, Xiao-Dong,Xu, Lan-Ping,Zhang, Xiao-Hui,et al. Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: No difference in the high-and low-risk groups[J]. INTERNATIONAL JOURNAL OF CANCER,2015,136(7):1697-1707.
APA Mo, Xiao-Dong.,Xu, Lan-Ping.,Zhang, Xiao-Hui.,Liu, Dai-Hong.,Wang, Yu.,...&Huang, Xiao-Jun.(2015).Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: No difference in the high-and low-risk groups.INTERNATIONAL JOURNAL OF CANCER,136(7),1697-1707.
MLA Mo, Xiao-Dong,et al."Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: No difference in the high-and low-risk groups".INTERNATIONAL JOURNAL OF CANCER 136.7(2015):1697-1707.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Mo, Xiao-Dong]的文章
[Xu, Lan-Ping]的文章
[Zhang, Xiao-Hui]的文章
百度学术
百度学术中相似的文章
[Mo, Xiao-Dong]的文章
[Xu, Lan-Ping]的文章
[Zhang, Xiao-Hui]的文章
必应学术
必应学术中相似的文章
[Mo, Xiao-Dong]的文章
[Xu, Lan-Ping]的文章
[Zhang, Xiao-Hui]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。